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the assumptions about the length of the treatment beneﬁt.
CONCLUSIONS: Anastrozole is a cost-effective alternative to
tamoxifen for the adjuvant treatment of postmenopausal women
with HR+ early breast cancer from the UK NHS perspective,
with the cost per QALY gained with anastrozole falling well
within the range considered acceptable for reimbursement in the
UK.
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OBJECTIVE: To estimate the cost and effects (measured in
QALYs) of fulvestrant as replacement of exemestane in the
second line treatment of postmenopausal women with advanced
breast cancer (ABC) in Greece. The preliminary results are pre-
sented in this analysis. METHODS: A Markov model was used
in order to compare cost effectiveness of two patient cohorts
receiving: fulvestrant (cohort A) or exemestane (cohort B) as 2nd
line treatment, megestrol acetate (A, B) as 3rd line treatment and
a palliative care package (A, B). The perspective of the study was
that of the National Health care System. Clinical evidence was
derived from published clinical trials. Treatment effects were esti-
mated in QALYs. Direct costs included drug therapy, oncologist
visits, monitoring tests and adverse events treatment. Informa-
tion on resource use was obtained from a panel of 3 oncology
key opinion leaders. As patients can use either public or private
sector, charges of both sectors for year 2005 will be used. Public
sector prices are used in this analysis. The time horizon of the
study was 11 years and the discount rate used for both costs and
QALYs was 3.5%. RESULTS: Cohort A had a higher propor-
tion of responders with a longer duration on 2nd line treatment.
In a cohort of 100 patients, fulvestrant produces 8.1 extra
QALYs at a 18% extra cost compared to exemestane resulting
in an incremental cost effectiveness ratio (ICER) of €35,633 per
QALY. However, as public sector charges highly underestimate
cost of treatment, further scenario analysis will be carried out in
order to capture true cost of treatment in Greece. CONCLU-
SIONS: Fulvestrant proves to be more beneﬁcial than exemes-
tane at an extra cost of €35,633 per QALY. Fulvestrant produces
extra beneﬁt with a reasonable extra cost for ABC patients in
Greece.
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OBJECTIVES: Four chemotherapy regimens: gemcitabine-
paclitaxel (Gem/Pac), paclitaxel in monotherapy (Pac), docetaxel
in monotherapy (Doc) and docetaxel-capecitabine in association
(Doc/Cap), are commonly used in the ﬁrst-line treatment of
metastatic breast cancer after anthracyclines failure. The purpose
of the study is to rank these strategies according to their incre-
mental cost-utility ratios. METHODS: A Markov model was
constructed in order to evaluate all 4 protocols, based on efﬁ-
cacy and tolerance data from recently published phase III studies.
Ravdin showed superiority for Doc compared to Pac in
monotherapy. O’Shaughnessy for the Doc/Cap regimen and the
phase III registration study for the Gem/Pac showed superiority
for Doc/Cap and Gem/Pac compared to Doc and Pac respec-
tively. An indirect comparison of these 4 regimens was con-
ducted, all possible scenarii with averages and extreme data were
tested. The costs were calculated by adding DRG costs, onerous
drug costs reimbursed over DRGs and transportation expenses.
Costs of severe toxicities, diagnosis and palliative care, were
taken into account. RESULTS: The Gem/Pac strategy appears to
be the most effective compared to Doc, Pac and Doc/Cap. In
terms of survival, Gem/Pac has an additional efﬁcacy of 16.5
weeks and an incremental cost-effectiveness (ICER) of €5570
compared to Doc/Cap, with a ICER of €18,000 per year of life
gained. In terms of survival adjusted to quality of life, the efﬁ-
cacy gain is 12.1 weeks and the ICER is €22,000 per year of life
gained. When the D8 gemcitabine is administered at home, the
Gem/Pac ICER is €12,000 year of life gained. CONCLUSION:
The incremental cost-effectiveness ratios of Gem/Pac regimen are
between €10,000 and €22,000 per year of life gained, still below
the limits recognized as reasonable at the international level.
Another advantage of the Gem/Pac combination therapy is to
allow home care on day 8 of the cycle.
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OBJECTIVES: Since January 1, 2004 several changes concern-
ing payment mechanisms became effective. These changes
include changes in drug costs (new deﬁnition for pharmacy add-
ups (affecting primarily very low and high priced drugs, and
mandatory manufacturer discounts), the introduction of a DRG-
system for hospital care and a new tariff system for private prac-
tices. The impact of these changes on health economic
evaluations using the third party payer perspective was evalu-
ated. METHODS: Resource utilization data for two different
intravenous therapies for an oncologic indication was collected
from 89 quarterly fee listings of ofﬁce based specialists in 2000.
Findings were projected to the hospital care setting and an oral
treatment option. The resource utilization data for each therapy
and treatment setting were analyzed 3 times: 1) drug costs, physi-
cian services and hospital per diem rates (2002); 2) drug costs,
physician services and hospital per diem rates (2004); and 3)
drug costs, physician services and hospital DRG rates (2005).
RESULTS: Compared to the 2002 analyses treatment cost in
2005 in private practices decreased by 3–18%, mainly due to
lower drug costs. Cost for hospital treatment changed in differ-
ent directions depending on the type of hospital. Treatment cost
in municipal hospitals increased by 52%–229%, whereas cost in
university hospitals decreased by 1%–65%. CONCLUSION:
Recent changes due to health care reforms and resulting changes
in payment mechanisms had a major impact on calculating treat-
ment costs from a third party payer perspective in Germany.
Although these results refer to an oncologic indication, it is very
likely that similar differences will be observed in other thera-
peutic areas as well. Results of health economic evaluations from
the third party payer perspective performed prior to 2005, 
particularly those involving hospital care and not using DRGs
may be misleading today and re-analysis should be seriously 
considered.
